Clopidogrel 75 mg/day significantly reduced fasting serum glucose by 22.77% and improved insulin sensitivity and oxidative stress markers compared to baseline in patients with type 2 diabetes.
RCT (n=42)
Placebo-controlled
Randomized into two groups
No
Does clopidogrel improve glycemic indices and oxidative stress in patients with uncontrolled type 2 diabetes?
Clopidogrel 75 mg/day for 2 months improved glycemic indices and reduced oxidative stress in patients with uncontrolled type 2 diabetes, but was associated with elevated liver enzymes.
Absolute Event Rate: 7.495% vs 9.33%
p-value: p=<0.05
Objective of present study is to evaluate the possible role of clopidogrel in improving glycemic indices and oxidative stress in patients with type 2 diabetes. This study was performed on 42 uncontrolled type 2 diabetic patients at the specialized center for Endocrinology and Diabetes, Al-Rasafa Directorate of Health, Baghdad. All of the patients were treated with (glibenclamide 5 mg at morning) and randomized into two groups: the first group includes 22 patients treated with clopidogrel tablets (75 mg/day) for 2 months; the second group includes 20 patients treated with a placebo formula (sodium bicarbonate 200 mg/day) for the same period. Treatment with clopidogrel produced significant improvement (P 0.05) in the serum levels of these two enzymes. In conclusion the treatment with clopidogrel improved glycemic indices and reduced oxidative stress in patients with type 2 diabetes.
Taher et al. (Thu,) conducted a rct in Type 2 diabetes (n=42). Clopidogrel vs. Placebo (sodium bicarbonate 200 mg/day) was evaluated on Fasting serum glucose (mmol/L) at 2 months (p=<0.05). Clopidogrel 75 mg/day significantly reduced fasting serum glucose by 22.77% and improved insulin sensitivity and oxidative stress markers compared to baseline in patients with type 2 diabetes.